登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688292 证券简称：浩瀚深度 公告编号：2025-073 转债代码：118052 转债简称：浩瀚转债 北京浩瀚深度信息技术股份有限公司 关于向2025年限制性股票激励计划激励对象 授予限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京浩瀚深度信息技术股份有限公司《2025年限制性股票激励计划（草案）》（以下简称"《激励计 划》"或"本激励计划"）规定的公司2025年限制性股票激励计划授予条件已经成就，根据北京浩瀚深度 信息技术股份有限公司（以下简称"公司"或"本公司"）2025年第一次临时股东大会授权，公司于2025年 11月18日召开第五届董事会第一次会议，审议通过了《关于向2025年限制性股票激励计划激励对象授予 限制性股票的议案》，确定以2025年11月18日为授予日，以17.00元/股为授予价格，向110名激励对象授 予327.5264万股限制性股票，现将有关事项说明如下： 一、2025年限制性股票激励计划授予情况 ...

Core Viewpoint - Zhongying Electronics (300327.SZ) has disclosed a draft for its 2025 restricted stock incentive plan, aiming to grant 1.9124 million shares of restricted stock to 74 incentive recipients at a price of 14.06 yuan per share [1] Group 1 - The incentive plan is effective from the date of completion of the registration of the restricted stock until the restricted stock is fully released from restrictions or repurchased and canceled, with a maximum duration of 72 months [1]

Group 1 - The core point of the article is that Zhongying Electronics (300327.SZ) has announced a restricted stock incentive plan for 2025, proposing to grant 1.9124 million shares to 74 incentive recipients at a price of 14.06 yuan per share [1] - The incentive plan will be effective from the date of completion of the registration of the restricted stock until the shares are fully released from restrictions or repurchased, with a maximum duration of 72 months [1]

Core Viewpoint - Yifeng Pharmacy has seen significant insider selling this year, with three executives and the controlling shareholder reducing their stakes, raising questions about the performance of the company's 2022 restricted stock incentive plan and whether executives have profited from it [1][2][3]. Group 1: Insider Selling - In 2025, Yifeng Pharmacy's controlling shareholder, Houxin Chuangtou, and its executives have completed share reduction plans, with a total of 24,248,200 shares sold, accounting for 2.00% of the total share capital [2]. - Executives including Gao Youcheng and Yan Jun have also sold shares, with prices ranging from 22 to 25 yuan [2][3]. - The upcoming share reductions by executives Wang Yonghui and Xiao Zaixiang involve a total of 213,900 shares [1]. Group 2: Performance of Incentive Plan - The shares sold by executives were obtained through the 2022 restricted stock incentive plan and capital reserve conversion [3][4]. - The 2022 incentive plan was deemed successful, meeting company performance assessment requirements [4][8]. - The performance targets for the incentive plan required a net profit increase of at least 20% in 2022 and 45% in 2023 compared to 2021 [5][6]. Group 3: Financial Performance - Yifeng Pharmacy's net profits from 2021 to 2024 were 888 million, 1.262 billion, 1.412 billion, and 1.529 billion yuan, showing growth rates of approximately 42.12%, 59.01%, and 72.18% respectively [7]. - Despite the growth in net profit, the company's revenue growth has slowed, with a reported revenue of 17.286 billion yuan in the first three quarters of 2025, a year-on-year increase of only 0.39% [8].

Core Points - The company has completed the second vesting period of its 2023 restricted stock incentive plan, with 61,699 shares being registered for 89 incentive recipients [1] - An additional 93,169 shares are in the process of being registered for repurchase [1] - The total share capital will increase to 169,646,246 shares after the vesting, which will dilute the basic earnings per share for the first three quarters of 2025, but will not significantly impact the financial condition and operating results [1] - The company has received subscription payments totaling 5.5536 million yuan from 162 incentive recipients [1] - The listing date for the vested shares is set for November 24, 2025 [1]

北京浩瀚深度信息技术股份有限公司 关于2025年限制性股票激励计划内幕信息 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688292 证券简称：浩瀚深度 公告编号：2025-071 转债代码：118052 转债简称：浩瀚转债 知情人买卖公司股票情况的自查报告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性承担个别及连带责任。 北京浩瀚深度信息技术股份有限公司（以下简称"公司"）于2025年10月22日召开第四届董事会第二十七 次会议、第四届监事会第二十四次会议分别审议通过了《关于〈北京浩瀚深度信息技术股份有限公司 2025年限制性股票激励计划（草案）〉及其摘要的议案》等相关议案，并于2025年10月23日在上海证券 交易所网站（www.sse.com.cn）上披露了相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）等有关法律、法规和规范性文件以及 公司相关内部制度的规定，公司对 2025 年限制性股票激励计划（以下简称"本次激励计划"）采取了充 分必要的保密措施，同时对本次激励计划的内幕信息知情人进行了登 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603192 证券简称：汇得科技 公告编号：2025-053 上海汇得科技股份有限公司关于 2024年限制性股票激励计划首次授予部分第一个 解除限售期解除限售条件成就暨上市流通的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 本次股票上市流通日期为2025年11月24日。 上海汇得科技股份有限公司（以下简称"公司"）于2025年11月17日召开了第四届董事会第六次会议，会 议审议通过了《关于公司2024年限制性股票激励计划首次授予部分第一个解除限售期解除限售条件成就 的议案》，根据《上市公司股权激励管理办法》《公司2024年限制性股票激励计划》（以下简称"本次 激励计划"或"本激励计划"）的相关规定及公司2024年第一次临时股东大会的授权，公司2024年限制性 股票激励计划第一个解除限售期解除限售条件已成就，公司董事会同意为符合条件的113名激励对象办 理限制性股票第一个解除限售期解除限售的相关手续，本次解除限售的限制性股票合计73.9 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688516 证券简称：奥特维 公告编号：2025-116 转债代码：118042 转债简称：奥维转债 无锡奥特维科技股份有限公司 关于2021年限制性股票激励计划 第二次预留授予部分 第三个归属期归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为25,302股（第二次预留授予部 分第三个归属期）。 本次股票上市流通总数为25,302股。 ● 本次股票上市流通日期为2025年11月24日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责任公司上海分公司有关业务 规则的规定，无锡奥特维科技股份有限公司（以下简称"公司"）于近日收到中国证券登记结算有限责任 公司上海分公司出具的《证券变更登记证明》，公司已完成2021年限制性股票激励计划（以下简称"本 激励计划"）第二次预留授予部分第三个归属期的股份登记工作。现将有关情况公告如下： 一、本次限制性股 ...

Core Viewpoint - Zhejiang Huaton Meat Products Co., Ltd. has completed the repurchase and cancellation of a portion of restricted stocks due to unmet performance targets, affecting the company's total share capital and stock structure [2][11][16]. Summary by Sections Stock Repurchase and Cancellation - The company repurchased and canceled 2,896,500 shares of restricted stock, which is 0.36% of the total share capital before the cancellation [2][15]. - The repurchase included 2,367,000 shares from the initial grant of the 2022 restricted stock incentive plan at a price of 8.53 CNY per share plus interest, and 529,500 shares from the reserved grant at a price of 7.30 CNY per share plus interest [2][13]. Approval and Disclosure Process - The company followed the necessary approval procedures for the incentive plan, including board and supervisory committee meetings, and public disclosures regarding the incentive objects [4][5][6]. - The company conducted internal announcements and received no objections during the public notice period [4][7]. Financial Details - The total amount paid for the repurchase was approximately 24,877,500.04 CNY, funded entirely by the company's own resources [13][14]. - The company’s total share capital decreased from 805,062,893 shares to 802,166,393 shares following the cancellation [15]. Impact on Company - The cancellation of the restricted stocks is not expected to significantly impact the company's financial status or operational results, nor will it affect the management team's motivation and stability [16].

Core Points - The company held its third extraordinary general meeting of shareholders on November 17, 2025, with no resolutions being rejected [2][3] - The meeting was conducted in compliance with relevant laws and regulations, with a combination of on-site and online voting [3][5] - All current directors and the board secretary attended the meeting, ensuring full representation [4] Meeting Details - The meeting took place at the Shenzhen Bay Technology Eco-park, with a total of 1,432,621 shares in the company's repurchase account not entitled to vote [2] - The chairman attended via telecommunication due to business travel, and the meeting was presided over by director Deng Haoran [3] Resolutions Passed - Three key resolutions related to the 2025 Restricted Stock Incentive Plan were approved, including the plan draft and its implementation management measures [5][6] - The resolutions received more than two-thirds approval from the voting shareholders present at the meeting [6] Legal Verification - The meeting was witnessed by lawyers from Beijing Jindu (Shenzhen) Law Firm, confirming that all procedures and voting results were lawful and valid [6]